The securities offered and sold by iSpecimen under the private placement have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), or the securities laws of the State and cannot be offered or sold in United States in the absence of registration with the Securities and Exchange Commission (the “SEC”) or an applicable exemption from these registration requirements. iSpecimen has agreed to file a registration statement with the SEC covering the resale of the common shares and the common shares underlying the warrants to be issued in connection with the private placement. Any resale of iSpecimen Common Shares under this Resale Registration Statement will be effected only by way of prospectus.
This press release does not constitute an offer to sell or the solicitation of an offer to buy, and there will be no sale of such securities in any state or jurisdiction in which such an offer, solicitation or sale would be illegal. before registration or qualification. under the securities laws of any such state or jurisdiction. The securities will not be registered under the Securities Act or any state securities law when issued upon closing of the private placement, and unless so registered, they cannot be offered or sold in United States except as an exemption from the registration requirements of the Securities Act and applicable state laws.
iSpecimen provides an online marketplace for human biospecimens, connecting life scientists from commercial and non-profit organizations with healthcare providers who have access to patients and specimens needed for medical discovery. Proprietary cloud-based technology enables scientists to intuitively search for samples and patients across a network of federated partners of hospitals, laboratories, biobanks, blood centers and other healthcare organizations. For more information on iSpecimen, please visit www.ispecimen.com.
This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements are characterized by future or conditional verbs such as “may”, “will”, “expect”, “intend”, “anticipate”, “believe”, “estimate” and “continue. Or similar words. read carefully any statements that contain these words, as they deal with future expectations and plans, which contain projections of future operating results or financial condition or state other forward-looking information.
Forward-looking statements are predictions, projections and other statements regarding future events that are based on current expectations and assumptions and, therefore, are subject to risks and uncertainties. There are many factors that could cause actual future events to differ materially from forward-looking statements contained in this press release, including, but not limited to, risk factors contained in documents filed by the Company with the SEC. , which can be viewed at www.sec.gov. Forward-looking statements speak only as of the date on which they are made. New risks and uncertainties arise over time, and it is not possible for the Company to predict these events or how they might affect the Company. If a change in events and circumstances reflected in the Company’s forward-looking statements occurs, the Company’s business, financial condition and results of operations may differ materially from those expressed in the Company’s forward-looking statements.
Readers are cautioned not to place undue reliance on forward-looking statements, and the Company assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information. , future events or otherwise.
For more information, please contact:
KCSA strategic communication
SOURCE iSpécimen Inc.